Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1782 - Risk of second malignancies after definitive therapy for esophageal cancer: a competing risk analysis


09 Sep 2017


Poster display session


Supportive Care and Symptom Management;  Therapy;  Oesophageal Cancer


Seiichiro Mitani


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


S. Mitani1, I. Oze2, S. Kadowaki1, T. Masuishi1, Y. Narita1, H. Taniguchi1, T. Ura1, M. Ando1, M. Tajika3, C. Makita4, T. Kodaira4, N. Uemura5, T. Abe5, K. Muro1

Author affiliations

  • 1 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 2 Division Of Molecular And Clinical Epidemiology, Aichi Cancer Center Research Institute, 464-8681 - Nagoya/JP
  • 3 Department Of Endoscopy, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 4 Department Of Radiation Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 5 Department Of Gastroenterological Surgery, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP


Abstract 1782


Esophageal cancer (EC) is associated with synchronous or metachronous cancer at other primary sites. However, few studies have evaluated second malignancies after treatment. We aimed to clarify the frequencies and risk factors of second malignancies after definitive therapy for EC.


EC patients (pts) who received definitive therapy at Aichi Cancer Center Hospital between 2000 and 2010 were retrospectively analyzed. Exclusion criteria were synchronous cancer or a past cancer history. We used competing risks regression model, which defined death and the development of second malignancies as competing risk, to conduct risk analyses. Standardized incidence rate (SIR) was calculated using population-based cancer registry.


A total of 758 pts were included. Patient characteristics were as follows: male, 84%; median age, 64 (range, 32–84) years; squamous cell carcinoma, 94%; upper-third/middle-third/lower-third, 19/49/31%; clinical stage 0–I/II/III/IV, 28/24/45/3%; alcohol consumption history, 87%; smoking history, 86%. Chemotherapy, surgery, radiotherapy and endoscopic therapy were performed in 579 (76%), 374 (49%), 349 (46%), and 107 (14%) pts, respectively. With a median follow-up of 3.7 years, a total of 131 second malignancies were observed in 106 patients (14%). Cumulative incidences of second malignancies after 5 years were 7.6%. SIR of the patients was 1.83 [95% confidence interval (CI): 1.50–2.22]. Most common primary tumor sites were head and neck (20%), followed by lung (17%), stomach (16%), and colon and rectum (11%). Risk analyses revealed that age ≥ 65 [subdistribution hazard ratio (sHR): 1.51, 95% CI: 1.01–2.24, vs.


EC pts are at a high risk of second malignancies after definitive treatment. Careful follow-up is required, especially in elderly pts or pts with early-stage.

Clinical trial identification

Legal entity responsible for the study

Aichi Prefecture




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.